Pfizer: 3 Key Takeaways for Long-Term Investors

Pfizer raised its 2026 revenue guidance to $62-64 billion, driven by strong performance from launched and acquired products with 32% operational revenue growth in Q3. The company is implementing $7.2 billion in cost-saving initiatives to offset upcoming patent expirations on key drugs. Management projects high single-digit revenue growth from 2028-2033, contingent on successfully converting late-stage oncology and obesity treatment trials into commercial revenue.